<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03561584</url>
  </required_header>
  <id_info>
    <org_study_id>2018P000019</org_study_id>
    <nct_id>NCT03561584</nct_id>
  </id_info>
  <brief_title>Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis</brief_title>
  <acronym>SHIP</acronym>
  <official_title>A Randomized, Placebo-controlled Pilot Study of Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis (PSC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blinded placebo controlled trial to assess the
      benefit of sulfasalazine in the treatment of PSC. The specific objectives of this study are
      to determine if sulfasalazine treatment 1) results in reduced serum ALP and other biomarkers
      of liver injury in PSC; 2) improves PSC patient symptoms; and 3) is safe in patients with
      PSC.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>There are two arms in this trial: active drug and placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>Participants and Providers will be masked until Week 14. If a subject continues past week 14, the study becomes Open-Label and participants are given the option to continue on the active drug for an additional 8 weeks.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in Mean Alkaline Phosphatase (ALP)</measure>
    <time_frame>Baseline through the end of the Study at Week 22</time_frame>
    <description>Proportion of patients with reduction of mean ALP &lt; 1.5 x ULN at end of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Normalization of ALP below the upper limit of normal</measure>
    <time_frame>Baseline through the end of the Study at Week 22</time_frame>
    <description>Assessment in number of patients whose ALP normalizes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall changes in ALP levels</measure>
    <time_frame>Baseline through the end of the Study at Week 22</time_frame>
    <description>Proportion of patients with ALP &gt; or &lt; 1.5 x ULN at end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in blood tests</measure>
    <time_frame>Baseline through the end of the Study at Week 22</time_frame>
    <description>Change in mean Liver Function Tests (e.g. Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), total bilirubin) and C-reactive Protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Baseline through the end of the Study at Week 22</time_frame>
    <description>Unexpected and Serious Adverse Events will be examined</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Mayo PSC risk score</measure>
    <time_frame>Baseline through the end of the Study at Week 22</time_frame>
    <description>Number of patients with changes in Mayo PSC risk score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Modified Fatigue Scale (MFS)</measure>
    <time_frame>Baseline through the end of the Study at Week 22</time_frame>
    <description>Number of patients with changes in MFS score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in pruritus visual analog scale (VAS)</measure>
    <time_frame>Baseline through the end of the Study at Week 22</time_frame>
    <description>Number of patients with changes in VAS score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Primary Sclerosing Cholangitis</condition>
  <arm_group>
    <arm_group_label>Active Drug (Sulfasalazine)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulfasalazine</intervention_name>
    <description>Patients will be initiated on a low dose of sulfasalazine (500 mg) twice daily (bid). Dosage will be increased throughout the study.</description>
    <arm_group_label>Active Drug (Sulfasalazine)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients will be initiated on 1 placebo tablet twice daily (bid). Dosage will be increased throughout the study.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 15-80

          2. A diagnosis of PSC for at least 6 months based upon cholangiography (ERCP or MRCP)
             demonstrating intrahepatic and/or extrahepatic biliary strictures, beading or
             irregularity consistent with PSC.

          3. ALP &gt; 1.67 times the upper limit of normal (ULN) at screening

          4. Inflammatory bowel disease

          5. Subject must either be on a stable dose of ursodeoxycholic acid for &gt; 6 months prior
             to screening or have been discontinued &gt; 4 weeks prior to screening (enrollment of
             patients who are on UDCA will be limited to 50% of all enrolled patients).

        Exclusion Criteria:

          1. Anticipated need for liver transplant within one year as determined by Mayo PSC risk
             score treatment

          2. Evidence of decompensated liver disease such as variceal bleeding, ascites, or hepatic
             encephalopathy.

          3. Evidence of advanced liver disease including MELD score &gt; 10, bilirubin &gt; 3.0,
             platelet count &lt; 100,000; or INR &gt; 1.4

          4. Concomitant chronic liver disease including alcohol related liver disease, chronic
             hepatitis B or C infection, haemochromatosis, Wilson's disease, alpha1-antitrypsin
             deficiency, non-alcoholic steatohepatitis, autoimmune hepatitis, or primary biliary
             cholangitis

          5. Secondary causes of sclerosing cholangitis

          6. Known intolerance to sulfasalazine (including but not limited to allergy to sulfa or
             mesalamine) or folic acid

          7. History of cholangiocarcinoma or colon cancer within 5 years

          8. History of colectomy with &gt; 1/3 bowel resected

          9. Treatment with any investigational agents, within two months or 5 half-lives of the
             investigational product, whichever is longer.

         10. Active illicit drug or alcohol abuse

         11. Current or past use of sulfasalazine within 6 months of enrollment.

         12. Treatment with antibiotics within 3 months of start of medication

         13. Need for chronic use of antibiotics

         14. Evidence of bacterial cholangitis within 6 months of enrollment

         15. In patients with Ulcerative Colitis, simple clinical colitis activity index of &gt; 4 or,
             if Crohn's disease, a Harvey-Bradshaw index of &gt; 5

         16. Chronic kidney injury (eGFR &lt; 59)

         17. Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fernanda Quevedo</last_name>
    <phone>617-732-9173</phone>
    <email>squevedo@bwh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joshua Korzenik, MD</last_name>
    <phone>617-732-9173</phone>
    <email>jkorzenik@bwh.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, Davis</name>
      <address>
        <city>Davis</city>
        <state>California</state>
        <zip>95616</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandeep Dhaliwal</last_name>
    </contact>
    <investigator>
      <last_name>Chris Bowlus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Elibero</last_name>
    </contact>
    <investigator>
      <last_name>Cynthia Levy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diane Sabogal, NP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arley Donovan</last_name>
    </contact>
    <investigator>
      <last_name>Dan Pratt, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernanda Quevedo</last_name>
      <phone>617-732-9173</phone>
      <email>squevedo@bwh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Joshua Korzenik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Rush</last_name>
    </contact>
    <investigator>
      <last_name>Stuart Gordon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Klebert</last_name>
    </contact>
    <investigator>
      <last_name>Scott McHenry</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mauricio Lisker-Melman</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christy Walters</last_name>
    </contact>
    <investigator>
      <last_name>Andrew Muir</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maureen Mccauley</last_name>
    </contact>
    <investigator>
      <last_name>David Goldberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LyTieng Huot</last_name>
    </contact>
    <investigator>
      <last_name>Kiran Bambha</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 14, 2018</study_first_submitted>
  <study_first_submitted_qc>June 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2018</study_first_posted>
  <last_update_submitted>January 27, 2020</last_update_submitted>
  <last_update_submitted_qc>January 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Joshua Korzenik</investigator_full_name>
    <investigator_title>Director, Crohn's and Colitis Center</investigator_title>
  </responsible_party>
  <keyword>Sclerosing</keyword>
  <keyword>Cholangitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Cholangitis, Sclerosing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sulfasalazine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

